Fresenius SE KGaAXSWX:FRE 71 Days Payable is 30.81 as of Mar. 2026, which is 3% above its 10-year median of 30.01. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF32.85 (Fairly Valued). The stock has 5 warning signs investors should review. Among 608 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 77.14% on this metric.
The historical rank and industry rank for Fresenius SE KGaA's Days Payable or its related term are showing as below:
XSWX:FRE'
s Days Payable Range Over the Past 10 Years
Min: 25.6 Med: 30.01 Max: 55.1
Current: 26.85
During the past 13 years, Fresenius SE KGaA's highest Days Payable was 55.10. The lowest was 25.60. And the median was 30.01.
XSWX:FRE's Days Payable is ranked worse than 77.14% of 608
companies
in the Healthcare Providers & Services industry
Industry Median: 58.08
vs XSWX:FRE: 26.85
Fresenius SE KGaA's Days Payable
declined
from Mar. 2025 (31.82) to Mar. 2026 (30.81).
It may suggest that Fresenius SE KGaAaccelerated paying its suppliers.
Fresenius SE KGaA Days Payable Related Terms
Fresenius SE KGaA Days Payable Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Days Payable Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Days Payable distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fresenius SE KGaA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (XSWX:FRE) has a Days Payable of 30.81 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fresenius SE KGaA and its competitors. This is near median its historical median of 30.01. Over the past decade, Fresenius SE KGaA's Days Payable has ranged from 25.60 to 55.10. According to the industry distribution chart, Fresenius SE KGaA ranks #469 out of 608 companies in the Healthcare Providers & Services industry, placing it in the top 77.1%.
Is Fresenius SE KGaA's Days Payable too high?
Fresenius SE KGaA's current Days Payable of 30.81 is near median its 10-year median of 30.01. Over the past 10 years, this metric has ranged from a low of 25.60 to a high of 55.10. The Healthcare Providers & Services industry median Days Payable is 58.08. Fresenius SE KGaA's value of 30.81 is 47% below this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #469 out of 608 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Days Payable compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #469 out of 608 companies for Days Payable. This places Fresenius SE KGaA in the lower half of its industry. The industry median Days Payable is 58.08. Fresenius SE KGaA's value of 30.81 is 47% below this benchmark. Historically, Fresenius SE KGaA's own Days Payable has ranged from 25.60 to 55.10 over the past decade. While the company's 10-year median is 30.01 vs. the industry median of 58.08, Fresenius SE KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.08, based on 608 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current Days Payable of 30.81 is 47% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Days Payable is 30.81, which is near median its own 10-year median of 30.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF32.85, compared to a current price of CHF35.86 — trading 9.2% above its estimated fair value. The current Days Payable is 30.81, which is near median its 10-year median of 30.01 and 47% below the Healthcare Providers & Services industry median of 58.08. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Days Payable is 30.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF35.86 is trading 9.2% above its estimated GF Value™ of CHF32.85.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for XSWX:FRE:
Days Payable: 30.81 (near median its 10-year median of 30.01)
GF Value™: CHF32.85 vs. price of CHF35.86 (9.2% above fair value)
Industry Position: 47% below the Healthcare Providers & Services median (#469 of 608)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score
Get the complete analysis for XSWX:FRE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
